Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07506395 · ClinicalTrials.gov registry record · Phase 1
Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder
A Phase 1 study, sponsored by University of New Mexico.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT07506395 is a Phase 1 study that is actively recruiting participants, run by University of New Mexico. The registered enrollment target is 36 participants.
The verdict
NCT07506395, a Phase 1 study, is actively recruiting participants, sponsored by University of New Mexico.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD severity.
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2028-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07506395
The ClinicalTrials.gov registry entry for NCT07506395 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT07506395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07506395 about?
NCT07506395 is a clinical study titled "Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder". This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individ...
What is the current status of trial NCT07506395?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2026-05-01. Estimated completion is 2028-05-01.
What interventions are being tested in trial NCT07506395?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT07506395?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.